177 related articles for article (PubMed ID: 10093692)
1. Weekly gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase II study.
Lippe P; Tummarello D; Monterubbianesi MC; Silva RR; Giuliodori L; Mari D; Santo A; Pasini F; Cetto GL; Rossi D; Porfiri E; Cascinu S; Cellerino R
Ann Oncol; 1999 Feb; 10(2):217-21. PubMed ID: 10093692
[TBL] [Abstract][Full Text] [Related]
2. A new cisplatin/gemcitabine schedule in locally advanced (IIIB) and metastatic (IV) non-small cell lung cancer: relationship between dose-intensity and efficacy. A phase II study.
Rossi D; Graziano F; Catalano V; Giordani P; Fedeli SL; Alessandroni P; Fedeli A; Dennetta D; Ugolini M; Catalano G
Anticancer Res; 2002; 22(5):3087-92. PubMed ID: 12530048
[TBL] [Abstract][Full Text] [Related]
3. Advanced non-small cell lung cancer in the elderly: effective and well tolerated weekly gemcitabine and cisplatin regimen. A pilot study.
Lippe P; Silva RR; Giuliodori L; Cancellieri MA; Battelli N; Massacesi C; Berardi R; Bisonni R; Gesuita R; Cellerino R
Minerva Med; 2000; 91(3-4):53-7. PubMed ID: 11037630
[TBL] [Abstract][Full Text] [Related]
4. Combination of gemcitabine and cisplatin for advanced non-small cell lung cancer: a phase II study with emphasis on scheduling.
Huisman C; Giaccone G; van Groeningen CJ; Sutedja G; Postmus PE; Smit EF
Lung Cancer; 2001; 33(2-3):267-75. PubMed ID: 11551422
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study.
Crinò L; Scagliotti G; Marangolo M; Figoli F; Clerici M; De Marinis F; Salvati F; Cruciani G; Dogliotti L; Pucci F; Paccagnella A; Adamo V; Altavilla G; Incoronato P; Trippetti M; Mosconi AM; Santucci A; Sorbolini S; Oliva C; Tonato M
J Clin Oncol; 1997 Jan; 15(1):297-303. PubMed ID: 8996156
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of gemcitabine and weekly cisplatin for advanced non-small cell lung cancer.
Shepherd FA; Cormier Y; Burkes R; Evans WK; Goss G; Klimo P; Feld R; Taylor M
Semin Oncol; 1997 Jun; 24(3 Suppl 8):S8-27-S8-30. PubMed ID: 9207313
[TBL] [Abstract][Full Text] [Related]
7. A randomized study comparing two different schedules of administration of cisplatin in combination with gemcitabine in advanced nonsmall cell lung carcinoma.
Ricci S; Antonuzzo A; Galli L; Tibaldi C; Bertuccelli M; Lopes Pegna A; Petruzzelli S; Bonifazi V; Orlandini C; Franco Conte P
Cancer; 2000 Oct; 89(8):1714-9. PubMed ID: 11042565
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of vinorelbine and gemcitabine for inoperable stage IIIB-IV non-small-cell lung cancer.
Isokangas OP; Knuuttila A; Halme M; Mäntylä M; Lindström I; Nikkanen V; Viren M; Joensuu H; Mattson K
Ann Oncol; 1999 Sep; 10(9):1059-63. PubMed ID: 10572603
[TBL] [Abstract][Full Text] [Related]
9. A phase II study with gemcitabine and split-dose cisplatin in patients with advanced non-small cell lung cancer.
Kim JH; Lee DH; Shin HC; Kwon JH; Jung JY; Kim HJ; Song HH; Lee KS; Zang DY; Ahn JS; Park YL; Lee JA
Lung Cancer; 2006 Oct; 54(1):57-62. PubMed ID: 16884818
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial assessing the combination of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC).
Antón A; Díaz-Fernández N; González Larriba JL; Vadell C; Masutti B; Montalar J; Barneto I; Artal A; Rosell R
Lung Cancer; 1998 Nov; 22(2):139-48. PubMed ID: 10022221
[TBL] [Abstract][Full Text] [Related]
11. Sequential therapy in advanced non-small-cell lung cancer with weekly paclitaxel followed by cisplatin-gemcitabine-vinorelbine. A phase II study.
Feliu J; Martin G; Lizón J; Chacón JI; Dorta J; de Castro J; Rodríguez A; Sánchez Heras B; Torrego JC; Espinosa E; González Barón M;
Ann Oncol; 2001 Oct; 12(10):1369-74. PubMed ID: 11762806
[TBL] [Abstract][Full Text] [Related]
12. Final results of the Canadian phase I dose escalation trial of gemcitabine and cisplatin for advanced non-small cell lung cancer.
Shepherd FA; Burkes RL; Cormier Y; Crump M; Feld R; Strack T; Schulz M
Semin Oncol; 1996 Oct; 23(5 Suppl 10):48-54. PubMed ID: 8893882
[TBL] [Abstract][Full Text] [Related]
13. A three-week schedule of gemcitabine-cisplatin in advanced non-small-cell lung cancer with two different cisplatin dose levels: a phase II randomized trial.
Rinaldi M; Crinò L; Scagliotti GV; Mosconi AM; De Marinis F; Gridelli C; Selvaggi G; Della Giulia M; Darwish S; Porrozzi S; Novello S; Cipri A; Bartolucci R; Calandri C; Tonato M
Ann Oncol; 2000 Oct; 11(10):1295-300. PubMed ID: 11106119
[TBL] [Abstract][Full Text] [Related]
14. Paclitaxel, cisplatin, and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic nonsmall cell lung carcinoma.
Rodriguez J; Cortes J; Calvo E; Azinovic I; Fernandez-Hildago O; Martinez-Monge R; Garzon C; de Irala J; Martinez-Aguillo M; Ramon Y Cajal T; Brugarolas A
Cancer; 2000 Dec; 89(12):2622-9. PubMed ID: 11135224
[TBL] [Abstract][Full Text] [Related]
15. Weekly gemcitabine and monthly cisplatin for advanced non-small cell lung carcinoma.
Abratt RP; Hacking DJ; Goedhals L; Bezwoda WR
Semin Oncol; 1997 Jun; 24(3 Suppl 8):S8-18-S8-23. PubMed ID: 9207311
[TBL] [Abstract][Full Text] [Related]
16. A phase I/II study of LY900003, an antisense inhibitor of protein kinase C-alpha, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer.
Villalona-Calero MA; Ritch P; Figueroa JA; Otterson GA; Belt R; Dow E; George S; Leonardo J; McCachren S; Miller GL; Modiano M; Valdivieso M; Geary R; Oliver JW; Holmlund J
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6086-93. PubMed ID: 15447994
[TBL] [Abstract][Full Text] [Related]
17. A phase II, open-label trial of bortezomib (VELCADE(®)) in combination with gemcitabine and cisplatin in patients with locally advanced or metastatic non-small cell lung cancer.
Kontopodis E; Kotsakis A; Kentepozidis N; Syrigos K; Ziras N; Moutsos M; Filippa G; Mala A; Vamvakas L; Mavroudis D; Georgoulias V; Agelaki S
Cancer Chemother Pharmacol; 2016 May; 77(5):949-56. PubMed ID: 26994909
[TBL] [Abstract][Full Text] [Related]
18. Decreased myelotoxicity of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC) with cisplatin infusion on day 15.
Cortesi E; Ramponi S; Corona M; Moscetti L; Grifalchi F; Oliva A; Lembo A; Gasperoni S; Padovani A
Lung Cancer; 2001; 31(2-3):271-6. PubMed ID: 11165407
[TBL] [Abstract][Full Text] [Related]
19. [Effectiveness of gemcitabine in combination with cisplatin in a randomized study of untreated patients with advanced non-small-cell lung carcinoma].
Mehić B; Zutić H; Dizdarević Z; Lomigorić J
Med Arh; 2004; 58(1):11-3. PubMed ID: 15017896
[TBL] [Abstract][Full Text] [Related]
20. Combined cisplatin and gemcitabine for non-small cell lung cancer: influence of scheduling on toxicity and drug delivery.
Abratt RP; Sandler A; Crinò L; Steward WP; Shepherd FA; Green MR; Nguyen B; Peters GJ
Semin Oncol; 1998 Aug; 25(4 Suppl 9):35-43. PubMed ID: 9728583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
